Medacta Group SA

Informe acción SWX:MOVE

Capitalización de mercado: CHF 2.9b

Medacta Group Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Francesco Siccardi

Chief Executive Officer (CEO)

€2.0m

Compensación total

Porcentaje del salario del CEO19.61%
Permanencia del CEO6.9yrs
Participación del CEOn/a
Permanencia media de la dirección12.3yrs
Promedio de permanencia en la Junta Directiva6.8yrs

Actualizaciones recientes de la dirección

Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why

May 01
Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01
We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Recent updates

Investor Optimism Abounds Medacta Group SA (VTX:MOVE) But Growth Is Lacking

Oct 01
Investor Optimism Abounds Medacta Group SA (VTX:MOVE) But Growth Is Lacking

Medacta Group's (VTX:MOVE) Solid Profits Have Weak Fundamentals

Sep 13
Medacta Group's (VTX:MOVE) Solid Profits Have Weak Fundamentals

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF150?

Sep 12
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF150?

Estimating The Fair Value Of Medacta Group SA (VTX:MOVE)

Aug 29
Estimating The Fair Value Of Medacta Group SA (VTX:MOVE)

Medacta Group (VTX:MOVE) Has Some Way To Go To Become A Multi-Bagger

Aug 01
Medacta Group (VTX:MOVE) Has Some Way To Go To Become A Multi-Bagger

Do Medacta Group's (VTX:MOVE) Earnings Warrant Your Attention?

Jun 24
Do Medacta Group's (VTX:MOVE) Earnings Warrant Your Attention?

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

May 24
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Market Participants Recognise Medacta Group SA's (VTX:MOVE) Earnings Pushing Shares 26% Higher

May 10
Market Participants Recognise Medacta Group SA's (VTX:MOVE) Earnings Pushing Shares 26% Higher

Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why

May 01
Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Apr 24
Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Return Trends At Medacta Group (VTX:MOVE) Aren't Appealing

Apr 10
Return Trends At Medacta Group (VTX:MOVE) Aren't Appealing

Medacta Group SA (VTX:MOVE) Yearly Results: Here's What Analysts Are Forecasting For This Year

Mar 28
Medacta Group SA (VTX:MOVE) Yearly Results: Here's What Analysts Are Forecasting For This Year

Medacta Group SA (VTX:MOVE) Looks Just Right With A 25% Price Jump

Feb 13
Medacta Group SA (VTX:MOVE) Looks Just Right With A 25% Price Jump
User avatar

New Products Like GMK SpheriKA And NextAR Will Strengthen Future Prospects In The Spine Segment

Medacta's innovation in product launches and medical education expansion drives revenue growth, with a strong focus on the Spine segment and ASCs.

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Jan 06
Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

The Price Is Right For Medacta Group SA (VTX:MOVE)

Nov 22
The Price Is Right For Medacta Group SA (VTX:MOVE)

Is Medacta Group (VTX:MOVE) A Risky Investment?

Oct 14
Is Medacta Group (VTX:MOVE) A Risky Investment?

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

Sep 06
Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Aug 21
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Aug 06
Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Jun 20
Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01
We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Apr 17
Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Mar 29
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Feb 22
Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Feb 07
Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Dec 18
Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Dec 04
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Nov 15
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Oct 30
Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Oct 17
If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Sep 29
Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Aug 11
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Jul 27
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

Jul 03
Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Apr 28
At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Is Medacta Group (VTX:MOVE) A Risky Investment?

Apr 08
Is Medacta Group (VTX:MOVE) A Risky Investment?

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dec 25
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Dec 09
Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Nov 09
Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

Sep 16
Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Aug 20
The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Jul 02
Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

May 28
Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

May 12
Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Mar 31
These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Mar 17
Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Feb 07
Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Dec 10
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Nov 05
Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Sep 30
Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Aug 26
Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Jul 20
Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

May 19
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Apr 05
We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Mar 02
What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Francesco Siccardi en comparación con los beneficios de Medacta Group?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2025n/an/a

€95m

Mar 31 2025n/an/a

€84m

Dec 31 2024€2m€392k

€73m

Sep 30 2024n/an/a

€65m

Jun 30 2024n/an/a

€56m

Mar 31 2024n/an/a

€52m

Dec 31 2023€2m€396k

€47m

Sep 30 2023n/an/a

€49m

Jun 30 2023n/an/a

€50m

Mar 31 2023n/an/a

€48m

Dec 31 2022€2m€372k

€46m

Sep 30 2022n/an/a

€47m

Jun 30 2022n/an/a

€47m

Mar 31 2022n/an/a

€49m

Dec 31 2021€2m€354k

€52m

Sep 30 2021n/an/a

€54m

Jun 30 2021n/an/a

€57m

Mar 31 2021n/an/a

€47m

Dec 31 2020€1m€339k

€37m

Sep 30 2020n/an/a

€24m

Jun 30 2020n/an/a

€10m

Mar 31 2020n/an/a

€11m

Dec 31 2019€843k€247k

€12m

Compensación vs. Mercado: La compensación total de Francesco($USD2.35M) está por encima de la media de empresas de tamaño similar en el mercado Swiss ($USD1.72M).

Compensación vs. Ingresos: La compensación de Francesco ha sido consistente con los resultados de la empresa en el último año.

CEO

Francesco Siccardi (48 yo)

6.9yrs
Permanencia
€1,997,619
Compensación

Dr. Francesco Siccardi has been Chief Executive Officer of Medacta Group SA since November 1, 2018. He is a Member of the Board of Directors of Surgical Practice Resource Group SA, Lugano since 2015 and of...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Alberto Siccardi
Founder & Non Executive Chairman7.8yrs€346.42ksin datos
Francesco Siccardi
Chief Executive Officer6.9yrs€2.00msin datos
Corrado Farsetta
Chief Financial Officer14.8yrssin datossin datos
Asif Hussain
Chief People Officerno datasin datossin datos
Alessandro Siccardi
Chief Supply Chain Officer9.8yrssin datossin datos
Filippo Cappelli
Head of ITno datasin datossin datos
Giovanni Galli
Chief Commercial Officerno datasin datossin datos
Massimiliano Bernardoni
Chief Innovation Officerno datasin datossin datos
Donato Cortesi
Secretary of the Boardno datasin datossin datos
Antonio Di Brino
Group Vice President of Finance & Taxno datasin datossin datos
12.3yrs
Permanencia media
52yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de MOVE es experimentado (12.3 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Alberto Siccardi
Founder & Non Executive Chairman7.8yrs€346.42ksin datos
Victor Balli
Lead Independent Director6.8yrs€228.29ksin datos
Riccardo Braglia
Independent Director4.8yrs€127.15ksin datos
Philippe Weber
Independent Director6.6yrs€150.26ksin datos
Maria Siccardi Tonolli
Non-executive Director7.8yrs€135.95ksin datos
6.8yrs
Permanencia media
65yo
Promedio de edad

Junta con experiencia: La junta directiva de MOVE se considera experimentada (6.8 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2025/10/06 05:41
Precio de las acciones al final del día2025/10/03 00:00
Beneficios2025/06/30
Ingresos anuales2024/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Medacta Group SA está cubierta por 11 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Samuel EnglandBerenberg
Christoph GretlerCredit Suisse
David AdlingtonJ.P. Morgan